| |
Physical QoL |
Mental QoL |
CES-D |
| |
β |
SE |
β |
SE |
β |
SE |
| Constant |
63.38** |
8.71 |
41.18** |
10.78 |
2.81 |
1.78 |
| Age |
0.06 |
0.12 |
0.19 |
0.14 |
-0.04† |
0.02 |
| Gender |
|
|
|
|
|
|
| Female vs. Male |
2.86 |
2.69 |
5.07† |
2.74 |
-0.47 |
0.47 |
| Time on ART |
|
|
|
|
|
|
| =< 6 months vs. > 6 months |
-7.88** |
2.28 |
0.19 |
2.29 |
0.27 |
0.39 |
| ART Combination |
|
|
|
|
|
|
| AZT + NVP + 3TC vs. AZT + EFV + 3TC |
-1.68 |
2.26 |
-4.89† |
2.62 |
0.87† |
0.46 |
| AZT + NVP + 3TC vs. All others |
0.55 |
2.12 |
0.89 |
2.52 |
-0.35 |
0.43 |
| CD4 Rank |
|
|
|
|
|
|
| < 200 vs. 200 – 350 |
-1.02 |
2.16 |
-3.26 |
2.40 |
0.12 |
0.41 |
| < 200 vs. 351 – 500 |
-2.57 |
2.66 |
-2.36 |
2.99 |
0.28 |
0.53 |
| < 200 vs. > 500 |
0.07 |
3.41 |
-4.54 |
3.86 |
0.01 |
0.68 |
| ART Knowledge |
-1.22 |
2.73 |
4.19 |
3.21 |
0.05 |
0.57 |
| Social Support |
0.13* |
0.05 |
0.12* |
0.06 |
-0.02* |
0.01 |
| HIV Stigma |
-0.21 |
0.15 |
-0.18 |
0.18 |
0.03 |
0.03 |
| Side-Effect Severity |
-6.85** |
1.23 |
-6.35** |
1.40 |
1.12** |
0.24 |
**P< 0.01; *p< 0.05; †p< 0.1; β = Estimated Coefficient Correlation; SE = Standard Error; Physical QoL = Physical Quality of Life; Mental QoL = Mental Quality of Life;
CES-D = Transformed Center for Epidemiologic Studies Depression Scale;Zidovudine (AZT); Nevirapine (NVP); lamivudine (3TC); Efavirenz (EFV). All the models were
further adjusted for covariates listed in table 2. |
